This study looked at the effect of two treatments (Zytiga (abiraterone) vs. Xtandi (enzalutamide)) for metastatic castration-resistant prostate cancer (mCRPC) on patient quality of life over 12 mo. Using established questionnaires, patients reported that they experienced less fatigue and cognitive impairments (including memory loss and reduced thinking abilities) with abiraterone acetate plus prednisone than with enzalutamide.
The study did not compare efficacy of each treatment, only quality of life issues as mentioned above. This finding occurred early after treatment initiation. This difference should be considered when choosing treatment, according to the authors.
The full text of this 2019 European Urology article can be accessed here: http://tiny.cc/ZytigaVsXtandi